Your body’s metabolism is like a high-performance engine. Over time, it builds up cellular waste or "junk". For decades, researchers sought a biological switch to trigger autophagy. This is a vital self-cleaning mode for cells. Rapamycin is the most promising switch discovered so far. It was originally found in the soil of Easter Island. The…

Cardiovascular disease remains the leading cause of mortality worldwide, with aging serving as the primary risk factor. As we age, the heart and blood vessels undergo progressive changes—including increased arterial stiffness, impaired relaxation (diastolic dysfunction), and a decline in endothelial health—often long before clinical symptoms appear. Rapamycin, an FDA-approved compound originally used in organ transplantation,…

The search for a true "fountain of youth" has shifted from mythical springs to the microscopic world of cellular signaling. At the center of this revolution is Rapamycin, an FDA-approved drug originally discovered in the soil of Easter Island in the 1970s. While its historical use involves preventing organ rejection in transplant patients, a wave…

The landscape of chronic illness treatment is shifting as researchers move beyond mere symptom management toward addressing the biological roots of exhaustion. As we move through 2026, a clear trend has emerged: rapamycin, once known primarily as a transplant drug and longevity "miracle," is being repurposed as a precision tool for patients battling Long COVID…

Rapamycin is the strongest drug candidate in longevity research so far, but it is not yet a proven “true anti-aging drug” in humans. The evidence is compelling in animals and promising in early human studies, yet we still lack the kind of large, long-term trials needed to say it reliably slows human aging. Rapamycin sits…

Instead of watching our canine companions succumb to the inevitable decline of age-related disease, the rapidly advancing field of canine geroscience is proactively targeting the biological roots of aging. At the forefront of this movement is a highly targeted pharmacological intervention: using rapamycin to selectively inhibit the mechanistic target of rapamycin (mTOR) pathway. By dialing…

People are tracking the latest breakthroughs in clinical longevity, already know that rapamycin has shifted from a niche immunosuppressant to the most heavily debated molecule in geroscience. But exactly why would a doctor prescribe rapamycin today? For decades, the FDA has approved rapamycin (known generically as sirolimus) specifically to prevent organ transplant rejection and treat…

Optimizing a Rapamycin Protocol for healthy aging is rapidly shifting from speculative biohacking to a data-driven clinical science. As more normative aging individuals look to geroprotective compounds, physicians and researchers are moving beyond the theoretical mechanisms of mTOR inhibition to focus on real-world pharmacokinetics, bioavailability, and precise dosing regimens. You are likely already aware that…

Navigating the landscape of geroprotectors requires a shift from traditional disease treatment to proactive biological optimization. Rapamycin dosing for longevity has moved beyond theoretical mouse models and into the clinics of specialty practitioners, yet the transition from a daily transplant drug to an intermittent anti-aging protocol requires precision to maximize autophagy while avoiding metabolic pitfalls.…